SCHEMBL6490499

SCHEMBL6490499

Nc1nc(CC(=O)N2CCN(c3ccc(NC(=O)C4=C(c5ccc(C(F)(F)F)cc5)CCCC4)cc3)CC2)cs1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 1/20 0.43
ME1 P48163 1/20 0.43
ME3 Q16798 1/20 0.43
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
LCK P06239 1/20 0.40
HCK P08631 1/20 0.40
SRC P12931 1/20 0.40
KDR P35968 1/20 0.40
LMNA P02545 3/20 0.40
HTT P42858 1/20 0.40
MAPKAPK2 P49137 1/20 0.40
MAPT P10636 6/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
CYP2C19 P33261 1/20 0.39
BTK Q06187 3/20 0.38
KCNH2 Q12809 1/20 0.38
CA2 P00918 2/20 0.37
CA12 O43570 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6502046 0.88 ME2 (0.41) ME2ME1ME3CCNCCDK8
SCHEMBL6500969 0.87 CCNC (0.45) ME2ME1ME3CCNCCDK8
SCHEMBL6500009 0.83 PHGDH (0.49) ME2ME1ME3CCNCCDK8
SCHEMBL6489500 0.81 TP53 (0.49) LMNAHTTMAPTPOLBMAPK1
SCHEMBL6489848 0.80 CCNC (0.44) ME2ME1ME3CCNCCDK8
SCHEMBL6503117 0.79 TP53 (0.47) LMNAHTTMAPTPOLBMAPK1
SCHEMBL6491110 0.77 SMN1; SMN2 (0.46) LMNAHTTMAPTALDH1A1POLB
SCHEMBL6501481 0.77 CA1 (0.52) LCKHCKSRCKDRLMNA
SCHEMBL6501876 0.76 CA1 (0.42) LCKHCKSRCKDRMAPKAPK2
SCHEMBL6490755 0.76 CA1 (0.51) LMNAMAPKAPK2MAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 ME2 1669/4885ME1 1825/4885ME3 3012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.